The short version of GLP-1 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Acylated GLP-1 receptor agonist | 31-residue synthetic peptide |
| Molecular formula | C187H291N45O59 | established for the free peptide |
| Appearance | White to off-white powder | as supplied before formulation |
| Solubility | Freely soluble in water | aqueous buffers near neutral pH |
| Typical storage | 2 to 8 degrees Celsius, protected from light | powder and solution forms differ in shelf life |
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
皮下注射后吸收相对缓慢，绝对生物利用度约为百分之八十九，血药浓度峰值通常出现在给药后一到三天。与白蛋白结合使清除减慢，终末半衰期约为一百六十五小时，接近一周。连续给药约四到五周后达到稳态暴露水平。表观分布容积约为每千克零点二五升，血浆蛋白结合率超过百分之九十九。代谢以蛋白水解切割和脂肪二酸侧链的 β-氧化为主，相关产物主要经尿液与粪便排出。
序列层面的改动同时解决了两个问题，即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟，主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库，使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发，属于该类药物化学改造的典型范式。
Semaglutide 是一种经结构修饰的胰高血糖素样肽-1 类似物，其主链与内源性 GLP-1(7-36) 约有百分之九十四的序列一致性。第 8 位丙氨酸被 α-氨基异丁酸取代，使二肽基肽酶-4 无法识别原有切割位点。第 34 位赖氨酸换为精氨酸，进一步降低酶解速率。第 26 位赖氨酸经间隔基连接一条含十八个碳的二酸脂肪链，该侧链赋予分子与血浆白蛋白结合的能力。
Stability studies examine how temperature, pH, and moisture influence degradation rates over time. In aqueous solution, hydrolysis and deamidation accelerate as pH moves away from mildly acidic conditions. Light exposure and residual metal ions can also trigger oxidation of susceptible residues. Accelerated aging at elevated temperature is used to estimate shelf life, though extrapolation to room temperature carries uncertainty because individual degradation pathways do not always scale predictably.
Lyophilized semaglutide powder is typically held at minus twenty degrees Celsius for long-term storage. At that temperature, solid-state degradation reactions proceed slowly and the peptide remains intact for extended periods. Repeated freeze-thaw cycles are best avoided because they promote aggregation and can shift the proportion of monomeric peptide present. Working aliquots are often prepared so that each portion is thawed only once, and desiccant is placed inside the vial to limit moisture uptake.
1H, the most commonly used spin-1/2 nucleus in NMR investigations, has been studied using many forms of NMR. Hydrogen is highly abundant, especially in biological systems. It is the nucleus providing the strongest NMR signal (apart from 3H, which is not commonly used due to its instability and radioactivity). Proton NMR has a narrow chemical-shift range but gives sharp signals in solution state. Fast acquisition of quantitative spectra (with peak integrals in stoichiometric ratios) is possible due to short relaxation time. The 1H nucleus has provided the sole diagnostic signal for clinical magnetic resonance imaging (MRI). 2H, a spin-1 nucleus, is commonly utilized to provide a signal-free medium in the form of deuterated solvents for proton NMR, to avoid signal interference from hydrogen-containing solvents in measurement of 1H NMR of solutes. It is also used in determining the behavior of lipids in lipid membranes and other solids or liquid crystals as it is a relatively non-perturbing label which can selectively replace 1H. Alternatively, 2H can be detected in media specially labeled with 2H. Deuterium resonance is commonly used in high-resolution NMR spectroscopy to monitor drift of the magnetic field strength (lock) and to monitor the homogeneity of the external magnetic field. 3He is very sensitive to NMR. It exists at a very low concentration in natural helium and can be purified from 4He. It is used mainly in studies of endohedral fullerenes, where its chemical inertness is beneficial to ascertaining the structure of the entrapping fullerene.
For an odd-numbered saturated fat (Cn), 0.5 * n - 1.5 oxidations are necessary, and the final process yields 8 acetyl CoA and 1 propionyl CoA. It is then converted to a succinyl CoA by a carboxylation reaction and generates additional 5 ATP (1 ATP is consumed in carboxylation process generating a net of 4 ATP). In addition, two equivalents of ATP are lost during the activation of the fatty acid. Therefore, the total ATP yield can be stated as:
== Personal life == Larson is married to Leslie Best. They have three children and reside in East Hartford. On February 11, 2025, while speaking on the floor of the House, Larson froze for about 30 seconds mid-sentence. His office later responded that it was likely an "adverse reaction" to new medication, and underwent tests conducted by the Attending Physician of the United States Congress. His office later clarified that Larson had experienced a complex partial seizure caused by a heart valve replacement fifteen years earlier. Larson returned to his duties and was present for voting on the House floor on February 13.
2.A.1 Major Facilitator superfamily (MFS), see also Lactose permease, Phosphate permease and Glucose transporter 2.A.2 The Glycoside-Pentoside-Hexuronide (GPH):Cation Symporter Family 2.A.3 The Amino Acid-Polyamine-Organocation (APC) Family 2.A.4 Cation diffusion facilitator (CDF) Family 2.A.5 Zinc (Zn2+)-Iron (Fe2+) Permease Family 2.A.6 Resistance-Nodulation-Cell Division Superfamily, see also SecDF protein-export membrane protein 2.A.7 The Drug/Metabolite Transporter (DMT) Superfamily 2.A.8 The Gluconate:H+ Symporter (GntP) Family 2.A.9 The Membrane Protein Insertase (YidC/Alb3/Oxa1) Family 2.A.10 The 2-Keto-3-Deoxygluconate Transporter (KdgT) Family 2.A.11 The Citrate-Mg2+:H+ (CitM) Citrate-Ca2+:H+ (CitH) Symporter (CitMHS) Family 2.A.12 ATP:ADP Antiporter Family 2.A.13 The C4-Dicarboxylate Uptake (Dcu) Family 2.A.14 Lactate Permease Family 2.A.15 The Betaine/Carnitine/Choline Transporter (BCCT) Family 2.A.16 Tellurite-resistance/Dicarboxylate Transporter Family 2.A.17 Proton-dependent Oligopeptide Transporter Family 2.A.18 The Amino Acid/Auxin Permease (AAAP) Family 2.A.19 The Ca2+:Cation Antiporter (CaCA) Family 2.A.20 The Inorganic Phosphate Transporter (PiT) Family 2.A.21 Solute:Sodium Symporter Family 2.A.22 The Neurotransmitter:Sodium Symporter Family 2.A.23 The Dicarboxylate/Amino Acid:Cation (Na+ or H+) Symporter (DAACS) Family 2.A.24 The 2-Hydroxycarboxylate Transporter (2-HCT) Family 2.A.25 Alanine or Glycine:Cation Symporter (AGCS) Family 2.A.26 The Branched Chain Amino Acid:Cation Symporter (LIVCS) Family 2.A.27 The Glutamate:Na+ Symporter (ESS) Family 2.A.28 Bile Acid:Na+ Symporter Family 2.A.29 Mitochondrial carrier Family 2.A.30 Cation-Chloride Cotransporter (CCC) Family 2.A.31 Anion Exchanger Family 2.A.32 The Silicon Transporter (Sit) Family 2.A.33 NhaA Na+:H+ Antiporter (NhaA) Family 2.A.34 The NhaB Na+:H+ Antiporter (NhaB) Family 2.A.35 The NhaC Na+:H+ Antiporter (NhaC) Family 2.A.36 Monovalent Cation:Proton Antiporter-1 (CPA1) Family 2.A.37 Monovalent Cation:Proton Antiporter-2 (CPA2) Family 2.A.38 K+ Transporter (Trk) Family 2.A.39 Nucleobase:Cation Symporter-1 (NCS1) Family 2.A.40 Nucleobase:Cation Symporter-2 (NCS2) Family 2.A.41 The Concentrative Nucleoside Transporter (CNT) Family 2.A.42 The Hydroxy/Aromatic Amino Acid Permease (HAAAP) Family 2.A.43 The Lysosomal Cystine Transporter (LCT) Family 2.A.45 Arsenite-Antimonite Efflux Family 2.A.46 The Benzoate:H+ Symporter (BenE) Family 2.A.47 Divalent Anion:Na+ Symporter (DASS) Family 2.A.48 The Reduced Folate Carrier (RFC) Family 2.A.49 Chloride Carrier/Channel (ClC) Family 2.A.50 The Glycerol Uptake (GUP) Family 2.A.51 The Chromate Ion Transporter (CHR) Family 2.A.52 The Ni2+-Co2+ Transporter (NiCoT) Family 2.A.53 Sulfate permease (SulP) Family 2.A.54 The Mitochondrial Tricarboxylate Carrier (MTC) Family 2.A.55 The Metal Ion (Mn2+-iron) Transporter (Nramp) Family 2.A.56 The Tripartite ATP-independent Periplasmic Transporter (TRAP-T) Family 2.A.57 The Equilibrative Nucleoside Transporter (ENT) Family 2.A.58 The Phosphate:Na+ Symporter (PNaS) Family 2.A.59 The Arsenical Resistance-3 (ACR3) Family 2.A.60 Organo Anion Transporter (OAT) Family 2.A.61 The C4-dicarboxylate Uptake C (DcuC) Family 2.A.62 The NhaD Na+:H+ Antiporter (NhaD) Family 2.A.63 The Monovalent Cation (K+ or Na+):Proton Antiporter-3 (CPA3) Family 2.A.64 Twin Arginine Targeting (Tat) Family 2.A.65 The Bilirubin Transporter (BRT) Family 2.A.66 The Multidrug/Oligosaccharidyl-lipid/Polysaccharide (MOP) Flippase Superfamily 2.A.67 The Oligopeptide Transporter (OPT) Family 2.A.68 The p-Aminobenzoyl-glutamate Transporter (AbgT) Family 2.A.69 The Auxin Efflux Carrier (AEC) Family 2.A.70 The Malonate:Na+ Symporter (MSS) Family 2.A.71 The Folate-Biopterin Transporter (FBT) Family 2.A.72 The K+ Uptake Permease (KUP) Family 2.A.73 The Short Chain Fatty Acid Uptake (AtoE) Family 2.A.74 The 4 TMS Multidrug Endosomal Transporter (MET) Family 2.A.75 The L-Lysine Exporter (LysE) Family 2.A.76 The Resistance to Homoserine/Threonine (RhtB) Family 2.A.77 The Cadmium Resistance (CadD) Family 2.A.78 The Branched Chain Amino Acid Exporter (LIV-E) Family 2.A.79 The Threonine/Serine Exporter (ThrE) Family 2.A.80 The Tricarboxylate Transporter (TTT) Family 2.A.81 The Aspartate:Alanine Exchanger (AAEx) Family 2.A.82 The Organic Solute Transporter (OST) Family 2.A.83 The Na+-dependent Bicarbonate Transporter (SBT) Family 2.A.84 The Chloroplast Maltose Exporter (MEX) Family 2.A.85 The Aromatic Acid Exporter (ArAE) Family 2.A.86 The Autoinducer-2 Exporter (AI-2E) Family (Formerly the PerM Family, TC #9.B.22) 2.A.87 The Prokaryotic Riboflavin Transporter (P-RFT) Family 2.A.88 Vitamin Uptake Transporter (VUT or ECF) Family 2.A.89 The Vacuolar Iron Transporter (VIT) Family 2.A.90 Vitamin A Receptor/Transporter (STRA6) Family 2.A.91 Mitochondrial tRNA Import Complex (M-RIC) (Formerly 9.C.8) 2.A.92 The Choline Transporter-like (CTL) Family 2.A.94 The Phosphate Permease (Pho1) Family 2.A.95 The 6TMS Neutral Amino Acid Transporter (NAAT) Family 2.A.96 The Acetate Uptake Transporter (AceTr) Family 2.A.97 The Mitochondrial Inner Membrane K+/H+ and Ca2+/H+ Exchanger (LetM1) Family 2.A.98 The Putative Sulfate Exporter (PSE) Family 2.A.99 The 6TMS Ni2+ uptake transporter (HupE-UreJ) Family 2.A.100 The Ferroportin (Fpn) Family 2.A.101 The Malonate Uptake (MatC) Family (Formerly UIT1) 2.A.102 The 4-Toluene Sulfonate Uptake Permease (TSUP) Family 2.A.103 The Bacterial Murein Precursor Exporter (MPE) Family 2.A.104 The L-Alanine Exporter (AlaE) Family 2.A.105 The Mitochondrial Pyruvate Carrier (MPC) Family 2.A.106 The Ca2+:H+ Antiporter-2 (CaCA2) Family 2.A.107 The MntP Mn2+ Exporter (MntP) Family 2.A.108 The Iron/Lead Transporter (ILT) Family 2.A.109 The Tellurium Ion Resistance (TerC) Family 2.A.110 The Heme Transporter, heme-responsive gene protein (HRG) Family 2.A.111 The Na+/H+ Antiporter-E (NhaE) Family 2.A.112 The KX Blood-group Antigen (KXA) Family 2.A.113 The Nickel/cobalt Transporter (NicO) Family 2.A.114 The Putative Peptide Transporter Carbon Starvation CstA (CstA) Family 2.A.115 The Novobiocin Exporter (NbcE) Family 2.A.116 The Peptidoglycolipid Addressing Protein (GAP) Family 2.A.117 The Chlorhexadine Exporter (CHX) family 2.A.118 The Basic Amino Acid Antiporter (ArcD) Family 2.A.119 The Organo-Arsenical Exporter (ArsP) Family 2.A.120 The Putative Amino Acid Permease (PAAP) Family 2.A.121 The Sulfate Transporter (CysZ) Family 2.A.122 The LrgB/CidB holin-like auxiliary protein (LrgB/CidB) Family 2.A.123 The Sweet; PQ-loop; Saliva; MtN3 (Sweet) Family 2.A.124 The Lysine Exporter (LysO) Family 2.A.125 The Eukaryotic Riboflavin Transporter (E-RFT) Family 2.A.126 The Fatty Acid Exporter (FAX) Family 2.A.127 Enterobacterial Cardiolipin Transporter (CLT) Family
== Chemistry == MCD peptide is a cationic 22-amino acid residue peptide with two disulfide bridges. Although the MCD peptide sequence shows similarity with apamin, they have different toxic properties. MCD peptide belongs to a large family composed of numerous derivatives detecting specific targets and displaying different toxic effects.
Sources: en.wikipedia.org
Retiform hemangioendothelioma (hobnail hemangioendothelioma) Schwannoma (acoustic neuroma, neurilemmoma, neurinoma, neurolemmoma, Schwann cell tumor) Solitary angiokeratoma Solitary cutaneous leiomyoma Solitary mastocytoma Solitary neurofibroma (plexiform neurofibroma, solitary nerve sheath tumor, sporadic neurofibroma) Spider angioma (nevus araneus, spider telangiectasia, spider nevus, vascular spider) Spindle cell hemangioendothelioma (spindle cell hemangioma) Spindle cell lipoma Sternal cleft Subungual exostosis Superficial acral fibromyxoma Systemic mastocytosis Targetoid hemosiderotic hemangioma (hobnail hemangioma) Telangiectasia Telangiectasia macularis eruptiva perstans Teratoma Tufted angioma (acquired tufted angioma, angioblastoma, angioblastoma of Nakagawa, hypertrophic hemangioma, progressive capillary hemangioma, tufted hemangioma) Umbilical granuloma Universal angiomatosis (generalized telangiectasia) Urticaria pigmentosa (childhood type of generalized eruption of cutaneous mastocytosis) Venous lake (phlebectasis) Wildervanck syndrome Xanthelasmoidal mastocytosis Zosteriform metastasis
The leaking veins responsible may be visualized by infusing a mixture of saline and x-ray contrast medium and performing a cavernosogram. In Digital Subtraction Angiography (DSA), the images are acquired digitally. Magnetic resonance angiography (MRA) This is similar to magnetic resonance imaging. Magnetic resonance angiography uses magnetic fields and radio waves to provide detailed images of the blood vessels. The doctor may inject into the patient's bloodstream a contrast agent, which causes vascular tissues to stand out against other tissues, so that information about blood supply and vascular anomalies is easier to gather. Erection Hardness Score
== Overview of religious studies work as characterized by Klaus von Stosch == Translated from German into English by Friederike von Schwerin-High (professor of German studies at Pomona College since 2005; PhD from UMass Amherst in comparative literature; research interests: narrative theory, translation studies and eighteenth-century literature). Klaus von Stosch, a comparative theologian from Bonn who has held the Chair of Systematic Theology at the University of Bonn since the 2021/2022 winter semester, has been familiar with Kermani's religious studies work since its inception and classifies it as follows: Even though Kermani does not consider himself a theologian, his texts on Islam and religious studies clearly go beyond a purely descriptive approach. In many places, the texts are a plea for a new take on the Koran and on Islamic tradition, but also for a more comprehensive view of other religions. Emphasizing the mystical, experiential dimension of religions, his texts tend to approach religion on an aesthetic level. However, his writings do not only address the union of human beings with God, which is paramount tomysticism, and to the associated notions of love and happiness. He is also concerned with the glory and terror of God, in other words, with all aspects of God's inexpressible mystery. From a theological point of view, Kermani attaches importance to the unity of God and the unity of all being in a decidedly classical sense. Everything comes from the One and returns to it—like the breath of human beings.
== Patents == US patent 3987302, George S. Hurst, Marvin G. Payne, Edward B. Wagner, "Resonance ionization for analytical spectroscopy", issued October 19, 1976 US patent 4,442,354, Hurst, G. Samuel, James E. Parks, James E. & Schmitt, Harold W, "Method of analyzing for a component in a sample", issued April 10, 1984
{\displaystyle {\begin{aligned}&{\frac {dS}{dt}}=-a(t)SI-v(t)S,\\[6pt]&{\frac {dI}{dt}}=a(t)SI-\mu (t)I-\psi (t)I,\\[6pt]&{\frac {dR}{dt}}=\mu (t)I,\\[6pt]&{\frac {dV}{dt}}=v(t)S,\\[6pt]&{\frac {dD}{dt}}=\psi (t)I\end{aligned}}}
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and neutral endopeptidases. Semaglutide carries a non-natural amino acid at position eight that blocks that cleavage, and a fatty diacid side chain that binds albumin. The result is a much longer duration of action than the native hormone.
The fatty diacid chain associates strongly with serum albumin, which keeps the peptide in circulation and shields it from rapid renal clearance. Bound peptide is released gradually, producing a sustained receptor signal. This mechanism also reduces the peak-to-trough variation seen with shorter-acting analogues.
The balance between peripheral receptor activation and signalling in the central nervous system is not fully resolved. The extent to which slowed gastric emptying accounts for reduced energy intake, compared with direct effects on appetite circuits, is debated. Long-term effects on lean mass and on tissues outside the gut and brain are still under study.
Native GLP-1 is a short-lived peptide cleared within one to two minutes by dipeptidyl peptidase-4 and related enzymes. Semaglutide keeps the receptor-binding backbone but adds substitutions and a lipid chain. These changes block the main cleavage site and allow reversible albumin binding, extending the half-life to roughly 165 hours.